AbbVie Stock Inches Toward 52-Week High as Shares Trade at $297.45

By TrendSpider Editor

The forward setup for AbbVie is shaped by the tension between strong price momentum and the overhead resistance that naturally accumulates near multi-year highs. AbbVie has long been a cornerstone of the large-cap pharmaceutical space, supported by its diversified immunology and oncology pipeline th

AbbVie Stock Inches Toward 52-Week High as Shares Trade at $297.45

AbbVie Inc. shares gained 0.87% on Thursday, November 12, 2026, pushing the stock to $297.45 and placing it within striking distance of its 52-week high of $302.93. The move comes after yesterday's session saw the stock trade in a range of $289.725 to $295.46, meaning today's price represents a meaningful step above that prior ceiling. With a 52-week low of $191.00, AbbVie has staged an impressive multi-month recovery, and bulls are now watching closely to see whether the stock can break through to fresh annual highs.

Key Drivers of the ABBV Stock Move

The forward setup for AbbVie is shaped by the tension between strong price momentum and the overhead resistance that naturally accumulates near multi-year highs. AbbVie has long been a cornerstone of the large-cap pharmaceutical space, supported by its diversified immunology and oncology pipeline that has helped sustain investor confidence following the wind-down of Humira exclusivity. With the stock now consolidating near the top of its annual range, the next directional move will likely be determined by either a catalyst-driven push through $302.93 or a pullback that tests whether prior resistance can convert to support. Traders and investors will be watching volume patterns closely over the coming sessions as a potential confirming signal for whichever direction ABBV resolves.

ABBV Seasonality

Mid-November historically marks a period when large-cap pharmaceutical names can see increased institutional activity tied to year-end portfolio rebalancing and tax-loss harvesting flows. For a stock sitting near its 52-week high heading into this window, that dynamic can cut both ways, either attracting momentum chasers looking to add to winners or prompting profit-taking from holders managing annual performance benchmarks.

ABBV Relative Performance

AbbVie's current price of $297.45 reflects a recovery of more than 55% from its 52-week low of $191.00, a performance trajectory that suggests ABBV has significantly outpaced broader defensive pharmaceutical peers over the trailing year. Yesterday's session range of $289.725 to $295.46 versus today's $297.45 print indicates that ABBV is trading with upward momentum relative to its own recent baseline, though a definitive peer-to-peer comparison would require additional sector price data not available in the current data set.

More on ABBV

Latest Market News